Functions of the BRCA1 end BRCA2 genes

Current Opinion in Genetics and Development

Volumn 8, Issue 1, 1998, Pages 14-20

  Bertwistle, David ^a   Ashworth, Alan ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; DNA; TRANSCRIPTION FACTOR; TUMOR PROTEIN;

ARTICLE; BREAST CANCER; CANCER GENETICS; CELL CYCLE; DNA REPAIR; ONCOGENE; PRIORITY JOURNAL; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE; ANIMAL; GENETIC TRANSCRIPTION; GENETICS; HUMAN; NEOPLASM; REVIEW;

ANIMALS; BRCA1 PROTEIN; BRCA2 PROTEIN; DNA REPAIR; HUMANS; NEOPLASM PROTEINS; NEOPLASMS; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC;

EID: 0031594639     PISSN: 0959437X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-437X(98)80056-7     Document Type: Article

References (62)

1. Szabo CA, King M-C. Inherited breast and ovarian cancer. Hum Mol Genet. 4:1995;1811-1817.
2. Stratton MR, Wooster R. Hereditary predisposition to breast cancer. Curr Opin Genet Dev. 6:1996;93-97.
3. Stratton MR. Recent advances in understanding of genetic susceptibility to breast cancer. Hum Mol Genet. 5:1996;1515-1519.
4. Easton D. Breast cancer genes - what are the real risks? of special interest Nat Genet. 16:1997;210-211 A useful brief review of current thinking on the risks of cancer in carriers of BRCA1 and BRCA2 mutations and the potential effects of modifying genes.
5. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 266:1994;66-71.
6. Saurin AJ, Borden KLB, Boddy MN, Freemont PS. Does this have a familiar RING? Trends Biochem. 21:1996;208-214.
7. Koonin EV, Altschul SF, Bork P. BRCA1 protein products: functional motifs. of special interest Nat Genet. 13:1996;266-268 See annotation [8].
8. Callebaut I, Mornon JP. From BRCA1 to RAP1: a widespread BRCT module closely associated with DNA repair. of special interest FEBS Letts. 400:1997;25-30 This paper and [7] indicate the presence of a weakly conserved motif in BRCA1 (the BRCT domain) which is also present in a wide range of proteins involved in DNA repair and metabolism. This suggests that BRCA1 and DNA repair proteins may have common binding proteins or common biochemical functions.
9. Wu LC, Wang ZW, Tsan JT, Spillman MA, Phung A, Xu XL, Wang MC, Hwang Ly Bowcock AM, Baer R. Identification of a RING protein that can interact in vivo with the BRCA1 gene product. of special interest Nat Genet. 14:1996;430-440 Isolation of the BARD1 gene by a two-hybrid screen using the RING finger region of BRCA1 as bait. Like BRCA1, BARD1 encodes a protein containing a RING finger and a BRCT domain.
10. Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, Collins N, Gregory S, Gumbs C, Micklem G, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature. 378:1995;789-791.
11. Tavtigian SV, Simard J, Rommens J, Couch F, Shattuck-Eidens D, Neuhausen S, Merajver S, Thorlacius S, Offit K, Stoppa-Lyonnet D, et al. The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet. 12:1996;333-337.
12. Bork P, Blomberg N, Nilges M. Internal repeats in the BRCA2 protein sequence. of special interest Nat Genet. 13:1996;22-23 See annotation [13].
13. Bignell G, Micklem G, Stratton MR, Ashworth A, Wooster R. The BRC repeats are conserved in mammalian BRCA2 proteins. of special interest Hum Mol Genet. 6:1997;53-58 In [12], eight copies of a 30-80 amino acid repeat are noted in part of the BRCA2 protein encoded by exon 11. In this paper, comparison of the sequences of BRCA2 exon 11 from six mammalian species demonstrates that this region of the gene is poorly conserved overall. The BRC repeats, however, are among a few highly conserved regions.
14. Gayther SA, Warren W, Mazoyer S, Russell PA, Harrington PA, Chiano M, Seal S, Hamoudi R, van Rensberg EJ, Dunning AM, et al. Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype-phenotype correlation. Nat Genet. 11:1995;428-433.
15. Gayther SA, Mangion J, Russell P, Seal S, Barfoot R, Ponder BAJ, Stratton MR, Easton D. Variation of risks of breast and ovarian cancer associated with different mutations of the BRCA2 gene. of special interest Nat Genet. 15:1997;103-105 This paper describes a genotype/phenotype correlation for a region of the BRCA2 gene, the OCCR, in which mutations predispose to ovarian rather than breast cancer. The mechanism for this remains obscure.
16. Thorlacius S, Olafsdottir G, Tryggvadottir L, Neuhausen S, Jonasson JG, Tavtigian SV, Tulinius H, Ogmundsdottir HM, Eyljord JE. A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes. of special interest Nat Genet. 13:1996;117-119 A nice genetic study in which the 999del5 BRCA2 mutant is shown to be associated with male breast cancer in some families but not in others, providing evidence for modifying genes for penetrance of this BRCA2 mutation.
17. Phelan CM, Rebbeck TR, Weber BL, Devilee P, Ruttledge MH, Lynch HT, Lenoir GM, Stratton MR, Easton DF, Ponder BAJ, et al. Ovarian cancer risk in BRCA1 carriers is modified by the HRAS1 variable number of tandem repeat (VNTR) locus. of special interest Nat Genet. 12:1996;309-311 Carriers of BRCA1 mutations harbouring one or two rare alleles at a VNTR linked to the Harvey - Ras proto-oncogene are at a modest (2.1 times) greater risk of ovarian but not breast cancer compared to carriers with common alleles. It is not clear whether this has anything to do with the Ras gene per se or is a marker of genomic instability.
18. Connor F, Smith A, Wooster R, Stratton M, Dixon A, Campbell E, Tait T-M, Freeman T, Ashworth A. Cloning, chromosomal mapping and expression pattern of the mouse Brca2 gene. of special interest Hum Mol Genet. 6:1997;291-300 A description of the amino acid sequence of mouse Brca2. Brca1 and Brca2 also appear to be evolving at similar rates and have overlapping patterns of expression within the adult mouse.
19. Marquis ST, Rajan JV, Wynshaw-Boris A, Xu J, Yin G-Y, Abel KJ, Weber BL, Chodosh LA. The developmental pattern of Brca1 expression implies a role in differentiation of the breast and other tissues. Nat Genet. 11:1995;17-26.
20. Lane TF, Deng C, Elson A, Lyu MS, Kozak CA, Leder P. Expression of Brca1 is associated with terminal differentiation of ectodermally and mesodermally derived tissues in mice. Genes Dev. 9:1995;2712-2722.
21. Rajan JV, Wang M, Marquis ST, Chodosh LA. Brca2 is coordinately regulated with Brca1 during proliferation and differentiation in mammary epithelial cells. Proc Natl Acad Sci USA. 93:1996;13078-13083.
22. Spillman MA, Bowcock AM. BRCA1 and BRCA2 mRNA levels are coordinately elevated in human breast cancer cells in response to estrogen. Oncogene. 13:1996;1639-1645.
23. Marks JR, Huper G, Vaughn JP, Davis PL, Norris J, McDonnell DP, Wiseman RW, Futreal PA, Iglehart JD. BRCA1 expression is not directly responsive to estrogen. Oncogene. 14:1997;115-121.
24. Vaughn JP, Davis PL, Jarboe MD, Huper G, Evans AC, Wiseman RW, Berchuck A, Iglehart JD, Futreal PA, Marks JR. BRCA1 expression is induced before DNA synthesis in both normal and tumour-derived breast cells. Cell Growth Diff. 7:1996;711-715.
25. Vaughn JP, Cirisano FD, Huper G, Berchuck A, Futreal PA, Marks JR, Inglehart JD. Cell cycle control of BRCA2. Cancer Res. 56:1996;4590-4594.
26. Chen Y, Farmer AA, Chen C-F, Jones DC, Chen P-L, Lee W-H. BRCA1 is a 220kDa nuclear phosphoprotein that is expressed and phosphorylated in a cell cycle-dependent manner. Cancer Res. 56:1996;3168-3172.
27. Ruffner H, Verma IH. BRCA1 is a cell cycle-regulated nuclear phosphoprotein. Proc Natl Acad Sci USA. 94:1997;7138-7143.
28. Breast Cancer Linkage Consortium Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. of outstanding interest Lancet. 349:1997;1505-1510 Comparison of tumours from carriers of BRCA1 and BRCA2 mutations with sporadic cases. Clear pathological differences are observed between the three groups, implying that the mechanism of tumourigenesis may be distinct in the three different types of tumour and different treatment regimens may be required.
29. Chen Y, Chen C-F, Riley DJ, Alfred DC, Chen P-L, Hoff DV, Osborne CK, Lee W-H. Aberrant subcellular localization of BRCA1 in breast cancer. Science. 270:1995;789-791.
30. Scully R, Ganesan S, Brown M, De Caprio JA, Cannistra SA, Feunteun J, Schnitt S, Livingston DM. Location of BRCA1 in human breast and ovarian cancer cells. of special interest Science. 272:1996;123-124 See annotation [31].
31. Chen Y, Chen P-L, Riley DJ, Lee W-H, Allred DC, Osborne CK. Location of BRCA1 in human breast and ovarian cancer cells. of special interest Science. 272:1996;125-126 In the papers of Chen et al. [29,31] and Scully et al. [30], there is an agreement that BRCA1 is a nuclear protein but Chen et al. contend that BRCA1 is cytoplasmic in breast cancer, suggesting an involvement in sporadic cancers.
32. Chen C-F, Li S, Chen Y, Chen P-L, Sharp ZD, Lee W-H. The nuclear localisation sequences of the BRCA1 protein interact with the importin-α subunit of the nuclear transport receptor. J Biol Chem. 271:1996;32863-32868.
33. Wilson CA, Payton MN, Elliot GS, Buaas FW, Cajulis EE, Grosshans D, Ramos L, Reese DM, Slamon DJ, Calzone FJ. Differential subcellular localisation, expression and biological toxicity of BRCA1 and the splice variant BRCA1-Δ11b. of special interest Oncogene. 14:1997;1-16 A detailed and carefully performed study indicating that BRCA1 is very difficult to overexpress in cells and may be toxic. This finding suggests that caution should be exercised when interpreting the results of experiments where BRCA1 is expressed ectopically.
34. Jensen RA, Thompson MA, Jetton TL, Szabo CI, Van der Meer R, Helou B, Tronick SR, Page DL, King M-C, Holt JT. BRCA1 is secreted and exhibits properties of a granin. of special interest Nat Genet. 13:1996;303-308 See annotation [36].
35. Wilson CA, Payton MA, Pekar SK, Zhang K, Pacifici RE, Gudas JL, Thukral S, Calzone FJ, Reese DM, Slamon DI. BRCA1 protein products: antibody specificity. of special interest Nat Genet. 13:1996;264-265 See annotation [36].
36. of outstanding interest Jensen RA, Thompson MA, Jetton TL, Van der Meer R, Helou B, Arteaga CL, Page DL, Holt JT, Tronick SR, Gown AM, et al. BRCA1 protein products: reply. of special interest Nat Genet. 13:1996;269-272 These papers [34-36] add another dimension to the BRCA1 controversy. Jensen et al. [34] suggested that BRCA1 is a secreted protein. Subsequently, Wilson et al. [35] demonstrated that a key antibody used by Jensen et al. to reach this conclusion cross-reacts with some type I receptor tyrosine kinases which are frequently overexpressed in breast cancer cells. Given this, and the weight of evidence in favour of a nuclear location for BRCA1 [26,27,29,30,31,32,33,49,51,53,54], the reply of Jensen et al. [36] is unconvincing.
37. Coene E, Van Oostveldt, Willems K, van Emmelo J, De Potter CR. BRCA1 is localised in cytoplasmic tube-like invaginations in the nucleus. of special interest Nat Genet. 16:1997;122-124 More fuel on the fire of the BRCA1 controversy (see also [29,30,31,32,33-36]. This paper reports the presence of BRCA1-containing tubes within the nucleus which appear to originate from the perinuclear region and contain the endoplasmic reticulum proteins 58K, β-COP and protein disulphide isomerase.
38. of special interest Gowen LC, Johnson BL, Latour AM, Sulik KK, Koller BH. Brca1 deficiency results in early embryonic lethality characterized by neuroepithelial abnormalities. of outstanding interest Nat Genet. 12:1996;191-194 See annotation [40].
39. of special interest Hakem R, de la Pompa JL, Sirard C, Mo R, Woo M, Hakem A, Wakeham A, Potter J, Reitmair A, Billia F, et al. The tumor suppressor gene Brca1 is required for embryonic cellular proliferation in the mouse. of outstanding interest Cell. 85:1996;1009-1023 See annotation [40].
40. -/- embryos described in Gowen et al. [38] survive several days later than those in [39,40,43].
41. -/- embryos are hypersensitive to γ-irradiation, providing the 'smoking gun' for an involvement of Brca2 in DNA repair.
42. Suzuki A, de la Pompa JL, Hakem R, Elia A, Yoshida R, Mo R, Nishina H, Chuang T, Wakeham A, Itie A, et al. Brca2 is required for embryonic cellular proliferation in the mouse. of outstanding interest Genes Dev. 11:1997;1242-1252 See annotation [41].
43. -/-.
44. Jacks T. Tumor suppressor gene mutations in mice. Annu Rev Genet. 30:1996;603-636.
45. Boyd M, Harris F, McFarlane R, Davidson HR, Black DM. A human BRCA1 gene knockout. Nature. 375:1995;541-542.
46. Wat1.
47. Chapman MS, Verma IM. Transcriptional activation by Brca1. of special interest Nature. 382:1996;678-679 See annotation [48].
48. Milner J, Ponder B, Hughes-Davies L, Seltmann M, Kouzarides T. Transcriptional activation functions in BRCA2. of special interest Nature. 386:1997;772-773 This paper and [47] report regions of BRCA1 and BRCA2 proteins which, when fused to GAL4, can act as transcriptional activators in yeast and mammalian cells. This property, however, has not yet been reported for the full-length proteins. In [48] the transcriptional activation domain is shown to contain weak sequence similarity to c-Jun and it is suggested that Jun-kinase (JNK)-like kinases might regulate BRCA2 activity.
49. Scully R, Anderson SF, Chao DM, Wei W, Ye L, Young RA, Livingston DM, Parvin JD. BRCA1 is a component of the RNA polymerase II holoenzyme. of special interest Proc Natl Acad Sci USA. 94:1997;5605-5610 BRCA1 was found to co-purify with the RNA polymerase II holoenzyme over multiple chromatographic steps whereas a mutant lacking the carboxy-terminal 11 amino acids did not associate with this complex. Rad51 has also been reported to be part of this complex by others (see [50]) but appears not to be present in the preparation reported here.
50. Maldonado E, Shiekhattar R, Sheldon M, Cho H, Drapkin R, Rickert P, Lees E, Anderson CW, Linn S, Reinberg D. A human RNA polymerase II complex associated with SRB and DNA-repair proteins. Nature. 381:1996;86-89.
51. Scully R, Chen J, Plug A, Xiao Y, Weaver D, Feunteun J, Ashley T, Livingston DM. Association of BRCA1 with Rad51 in mitotic and meiotic cells. of outstanding interest Cell. 88:1997;265-275 This splendid paper demonstrates co-localisation of BRCA1 and Rad51 in discrete nuclear foci during S phase in mitotic cells. Moreover, the two proteins are shown to associate by co-immunoprecipitation. This association suggests a role for BRCA1 in DNA repair. In human meiotic cells, the BRCA1 and Rad51 proteins are associated with unsynapsed elements of the synaptonemal complex suggesting a role in recombination.
52. Ivanov EL, Haber JE. DNA repair: RAD alert. Curr Biol. 7:1997;492-495.
53. + replication structures which implies an interaction with damaged replicating DNA. Phosphorylation of BRCA1 in response to DNA damage (also described in [54]) by an unknown kinase that appears to be neither ATM nor DNA-PK is also described.
54. Thomas JE, Smith M, Tonkinson JL, Rubinfeld B, Polakis P. Induction of phosphorylation on BRCA1 during the cell cycle and after DNA damage. of special interest Cell Growth Diff. 8:1997;801-809 See annotation [53].
55. Kinzler KW, Vogelstein B. Gatekeepers and caretakers. Nature. 386:1997;761-763.
56. Brugarolas J, Jacks T. Double indemnity: p53, BRCA and cancer, p53 mutation partially rescues developmental arrest in Brca1 and Brca2 null mice, suggesting a role for familial breast cancer genes in DNA damage repair. Nat Med. 3:1997;721-722.
57. Crook T, Crossland S, Crompton MR, Osin P, Gusterson BA. p53 mutations in BRCA1-sdassociated familial breast cancer. of outstanding interest Lancet. 350:1997;638-639 In sporadic breast cancer, the frequency of p53 mutation is ≈20-40%. The authors of this paper make the very important observation of high frequency mutation of p53 in tumours from carriers of BRCA1 mutations.
58. Fukasawa K, Choi T, Kuriyama R, Rulong S, Van de Woude GF. Abnormal centrosome amplification in the absence of p53. Science. 271:1996;1744-1747.
59. Mazoyer S, Dunning AM, Serova O, Dearden J, Puget N, Healey CS, Gayther SA, Mangion J, Stratton MR, Lynch HT, et al. A polymorphic stop codon in BRCA2. of special interest Nat Genet. 14:1996;253-254 A polymorphic variant in exon 27 of the BRCA2 gene results in the introduction of a stop codon and loss of the last 93 amino acids of the protein, including a putative 'granin' motif [34]. This appears to have no obvious phenotypic consequences.
60. Bertwistle D, Swift S, Marston NJ, Jackson LE, Crossland S, Crompton MR, Marshall CJ, Ashworth A. Nuclear location and cell cycle regulation of the BRCA2 protein. of special interest Cancer Res. 57:1997;5485-5488 Characterisation of the BRCA2 product, which is shown to be localised to the nucleus and regulated during the cell cycle. These observations are consistent with the suggested roles for BRCA2 in DNA repair and transcriptional regulation.
61. Connor F, Bertwistle D, Mee PJ, Ross GM, Swift S, Grigorieva E, Tybulewicz VLJ, Ashworth A. Tumorigenesis and a DNA repair defect in mice with a truncating Brca2 mutation. of outstanding interest Nat Genet. 17:1997;423-430 Previously reported mutations of the Brca2 gene [41-43], were lethal early in embryogenesis when homozygous. This paper reports the generation of viable Brca2 mutant mice which survive to develop thymic lymphomas. In addition, a role for Brca2 in DNA repair is directly demonstrated in fibroblasts from Brca2 mutant embryos.
62. Wong AKC, Pero R, Ormonde PA, Tavtigan SV, Bartel PL. RAD51 interacts with the evolutionary conserved BRC motifs in the human breast cancer susceptibility gene brca2. of special interest J Biol Chem. 272:1997;31941-31944 Using the yeast two-hybrid and biochemical assays, the authors demonstrate that the eight BRC repeats present in the BRCA2 protein interact specifically with the Rad51 protein.